TARGET Post-Approval Study

Completed

Conditions studied: Complex Regional Pain Syndrome (CRPS)

In brief

The purpose of this prospective, multicenter, single arm post-approval study is to demonstrate continued safety of the Axium and Proclaim Neurostimulator System for dorsal root ganglion (DRG) stimulation. The primary endpoint is the 12-month serious adverse event rate for permanent implants.

Key facts

Study ID
NCT02800863
Run by
Abbott Medical Devices
People needed
426
Starts
2016-08-23
Expected to finish
2021-09-23
Last updated by the study team
2024-07-08

Who can join

Age: 22 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.